{"id":"nepafenac-0-3-oph-susp","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or stinging"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Photophobia"},{"rate":null,"effect":"Corneal erosion or ulceration"}]},"_chembl":{"chemblId":"CHEMBL1021","moleculeType":"Small molecule","molecularWeight":"254.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nepafenac is a prodrug that is converted to amfenac in ocular tissues, where it inhibits COX-1 and COX-2 enzymes. This reduces the synthesis of prostaglandins, which are key mediators of inflammation and pain. The ophthalmic suspension formulation delivers the drug directly to the anterior segment of the eye to suppress ocular inflammation.","oneSentence":"Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin production and inflammation in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:50.736Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reduction of ocular inflammation and associated pain following cataract surgery"},{"name":"Reduction of ocular pain associated with corneal refractive surgery"}]},"trialDetails":[{"nctId":"NCT07178639","phase":"NA","title":"Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery","status":"RECRUITING","sponsor":"Nemocnice Kolín","startDate":"2025-08-01","conditions":"Macular Oedema, Cataract Surgery, NSAID (Non-Steroidal Anti-Inflammatory Drug)","enrollment":150},{"nctId":"NCT03499873","phase":"PHASE3","title":"Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2018-03-28","conditions":"Cataract","enrollment":448},{"nctId":"NCT03597867","phase":"PHASE3","title":"PGE2 Levels in Patient Treated With NSAIDs","status":"COMPLETED","sponsor":"University of Trieste","startDate":"2018-04-25","conditions":"Ocular Inflammation","enrollment":104},{"nctId":"NCT03406689","phase":"NA","title":"Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections","status":"COMPLETED","sponsor":"University Hospital of Patras","startDate":"2017-09-01","conditions":"Pain","enrollment":99}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nepafenac 0.3%","NEVANAC EY.DRO.SUS 3MG/ML"],"phase":"phase_3","status":"active","brandName":"Nepafenac 0.3% Oph Susp","genericName":"Nepafenac 0.3% Oph Susp","companyName":"Actavis Inc.","companyId":"actavis-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin production and inflammation in the eye. Used for Reduction of ocular inflammation and associated pain following cataract surgery, Reduction of ocular pain associated with corneal refractive surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}